Trials / No Longer Available
No Longer AvailableNCT05392374
Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Jazz Pharmaceuticals · Industry
- Sex
- —
- Age
- 6 Months – 18 Years
- Healthy volunteers
- —
Summary
This is an intermediate-size expanded access protocol to provide ONC201 to patients with diffuse intrinsic pontine gliomas who cannot access ONC201 through clinical trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ONC201 | ONC201 is an oral, small molecule selective antagonist of DRD2 |
Timeline
- First posted
- 2022-05-26
- Last updated
- 2022-05-26
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05392374. Inclusion in this directory is not an endorsement.